Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q644675> ?p ?o }
Showing triples 1 to 41 of
41
with 100 triples per page.
- Q644675 subject Q7139608.
- Q644675 subject Q8728165.
- Q644675 subject Q8808791.
- Q644675 subject Q8844626.
- Q644675 subject Q8965786.
- Q644675 abstract "Lasofoxifene (INN) (proposed tradename Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published online November 4 in The Journal of the National Cancer Institute.In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis.On January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn. Lasofoxifene was approved in the EU under the brand name Fablyn by the EMEA in March 2009.Lasofoxifene is a desmethyl dihydro analog of nafoxidine.".
- Q644675 atcPrefix "G03".
- Q644675 atcSuffix "XC03".
- Q644675 casNumber "180916-16-9".
- Q644675 fdaUniiCode "337G83N988".
- Q644675 iupacName "(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol".
- Q644675 pubchem "216416".
- Q644675 thumbnail Lasofoxifene.png?width=300.
- Q644675 wikiPageExternalLink www.lasofoxifene.com.
- Q644675 wikiPageWikiLink Q1368197.
- Q644675 wikiPageWikiLink Q165328.
- Q644675 wikiPageWikiLink Q204711.
- Q644675 wikiPageWikiLink Q206921.
- Q644675 wikiPageWikiLink Q4007235.
- Q644675 wikiPageWikiLink Q6958201.
- Q644675 wikiPageWikiLink Q7139608.
- Q644675 wikiPageWikiLink Q824258.
- Q644675 wikiPageWikiLink Q8728165.
- Q644675 wikiPageWikiLink Q8808791.
- Q644675 wikiPageWikiLink Q8844626.
- Q644675 wikiPageWikiLink Q8965786.
- Q644675 wikiPageWikiLink Q903917.
- Q644675 atcPrefix "G03".
- Q644675 atcSuffix "XC03".
- Q644675 casNumber "180916".
- Q644675 iupacName "-6".
- Q644675 pubchem "216416".
- Q644675 unii "337".
- Q644675 type ChemicalSubstance.
- Q644675 type Drug.
- Q644675 type ChemicalObject.
- Q644675 type Thing.
- Q644675 type Q8386.
- Q644675 comment "Lasofoxifene (INN) (proposed tradename Fablyn) is a non-steroidal selective estrogen receptor modulator (SERM) which is under development by Pfizer for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND).".
- Q644675 label "Lasofoxifene".
- Q644675 depiction Lasofoxifene.png.